Pulmozyme Side Effects
Generic name: dornase alfa
Medically reviewed by Drugs.com. Last updated on Jan 27, 2024.
Note: This document contains side effect information about dornase alfa. Some dosage forms listed on this page may not apply to the brand name Pulmozyme.
Applies to dornase alfa: inhalation solution.
Serious side effects of Pulmozyme
Along with its needed effects, dornase alfa (the active ingredient contained in Pulmozyme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking dornase alfa:
More common
- Body aches or pain
- chest pain
- congestion
- cough
- dryness or soreness of the throat
- fever
- hoarseness
- runny nose
- tender, swollen glands in the neck
- trouble breathing
- trouble swallowing
- voice changes
Other side effects of Pulmozyme
Some side effects of dornase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Rash
- sneezing
- stuffy nose
Less common
- Acid or sour stomach
- belching
- burning, dry, or itching eyes
- discharge or excessive tearing
- heartburn
- indigestion
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- stomach discomfort, upset, or pain
For Healthcare Professionals
Applies to dornase alfa: inhalation solution.
Dermatologic
Very common (10% or more): Rash (up to 12%)
Rare (less than 0.1%): Urticaria[Ref]
Musculoskeletal
Very common (10% or more): Chest pain (up to 25%)[Ref]
Other
Very common (10% or more): Fever (up to 32%), voice alteration (up to 18%)[Ref]
Respiratory
Very common (10% or more): Pharyngitis (up to 40%), rhinitis (up to 30%), dyspnea (up to 17%)
Common (1% to 10%): Laryngitis, Force Vita Capacity (FVC) decreased of 10% of predicted
Rare (less than 0.1%): Chest pain (pleuritic/non-cardiac), dysphonia, pulmonary function tests decreased[Ref]
Gastrointestinal
Common (1% to 10%): Dyspepsia[Ref]
Immunologic
Common (1% to 10%): Development of serum antibodies (2% to 4%)[Ref]
Ocular
Common (1% to 10%): Conjunctivitis[Ref]
More about Pulmozyme (dornase alfa)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Dosage information
- During pregnancy
- Drug class: miscellaneous respiratory agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Bryson HM, Sorkin EM. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs. 1994;48:894-906.
2. Witt DM, Anderson L. Dornase alfa: a new option in the management of cystic fibrosis. Pharmacotherapy. 1996;16:40-8.
3. Product Information. Pulmozyme (dornase alfa). Genentech. 2001;PROD.
4. Cerner Multum, Inc. UK Summary of Product Characteristics.
5. Cerner Multum, Inc. Australian Product Information.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
